Other
Indications for NOAC discontinuation according to bleeding risks - case report
Nada Ivičević
orcid.org/0000-0003-4759-7302
; Dom zdravlja Splitsko-dalmatinske županije
Marion Tomičić
orcid.org/0000-0003-2148-3227
; School of Medicine, University of Split, Split, Croatia
Abstract
Vitamin K antagonists (eg warfarin) and new oral anticoagulants (NOAC) are used to prevent stroke and other embolic accidents in patients with non-valvular atrial fibrillation and in the management and prevention of venous thromboembolism. The choice and dosage of NOACs depends on renal function. Threfore it is necessary to determine creatinine clearance before their introduction. Special caution must be paid to patients with comorbidity and to drug interactions. Treatment with NOACs is particular challenge in the cases such as a major bleeding or surgical intervention.
Keywords
anticoagulants; vitamin K – antagonists; warfarin; stroke; atrial fibrillation; preoperative care
Hrčak ID:
230751
URI
Publication date:
20.12.2019.
Visits: 1.809 *